

Supplementary Material

Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction

Supplementary Table 1. Overview of published sensitivities and specificities of AD and PD protein-related biomarkers

<i>Biomarker</i>	<i>Sensitivity</i>	<i>Specificity</i>
<i>AD markers</i>		
CSF p τ /Ab ratio (conversion from MCI to AD)	80-96% *	33-95% *
A β PET (AD diagnosis)	89.6% **	87.2% **
τ PET (AD diagnosis)	92.3-100% ***	52-92% ***
<i>PD markers</i>		
CSF t- α -syn	70-72% [60]	52-83% [60]
CSF o- α -syn	75.0% [62]	87.5% [62]
CSF o/t- α -synuclein ratio	89.3% [62]	90.6% [62]
α -syn RT-QuIC	92-95% [114]	100% [114]

*Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S (2017) CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev* **3**, CD010803.

Yeo JM, Waddell B, Khan Z, Pal S (2015) A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease. *Alzheimers Dement (Amst)* **1, 5-13.

***Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Trucocchio SP, Aldea P, Flitter M, Locascio T, Devine M, Siderowf A, Beach TG, Montine TJ, Serrano GE, Curtis C, Perrin A, Salloway S, Daniel M, Wellman C, Joshi AD, Irwin DJ, Lowe VJ, Seeley WW, Ikonovic MD, Masdeu JC, Kennedy I, Harris T, Navitsky M, Souhekal S, Mintun MA; A16 Study Investigators (2020) Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. *JAMA Neurol* **77**, 829-839.